Gilead’s Biktarvy reinforced as a treatment option for HIV
HIV affects approximately 39 million people worldwide and can lead to AIDS
Read More
Tag: Gilead Sciences
Gilead reveals positive results for domvanalimab
Study uses carious drug combinations to increase survival among lung cancer patients
Read More
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy
Data from two Phase III studies demonstrated durable viral suppression in HIV-1 patients
Read More
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B
Companies will collaborate on a combination therapy study
Read More
Intercept’s fatty liver drug one step closer to approval
Intercept Pharmaceuticals has announced that its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
